Prestige Consumer Healthcare Inc. $PBH Shares Sold by Dimensional Fund Advisors LP

Key Points

• Dimensional Fund Advisors LP reduced its stake in Prestige Consumer Healthcare by 6.5%, holding approximately 2.72 million shares worth $233.55 million at the end of the first quarter.
• Analysts have mixed views on Prestige Consumer Healthcare, with rating adjustments including a downgrade to "hold" by Wall Street Zen and target price reductions from Canaccord Genuity, now sitting at $100.
• Prestige Consumer Healthcare's latest earnings report revealed EPS of $0.95, missing estimates, and a revenue decline of 6.6% year-over-year at $249.53 million.

Dimensional Fund Advisors LP decreased its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 6.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,716,712 shares of the company's stock after selling 190,354 shares during the quarter. Dimensional Fund Advisors LP owned about 5.48% of Prestige Consumer Healthcare worth $233,551,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of PBH. Kayne Anderson Rudnick Investment Management LLC purchased a new stake in Prestige Consumer Healthcare during the fourth quarter valued at $84,932,000. Invesco Ltd. raised its stake in shares of Prestige Consumer Healthcare by 24.7% in the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company's stock valued at $113,635,000 after acquiring an additional 261,537 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Prestige Consumer Healthcare by 1,073.3% in the fourth quarter. BNP Paribas Financial Markets now owns 203,903 shares of the company's stock valued at $15,923,000 after acquiring an additional 186,524 shares during the period. GAMMA Investing LLC raised its stake in shares of Prestige Consumer Healthcare by 11,580.3% in the first quarter. GAMMA Investing LLC now owns 161,538 shares of the company's stock valued at $13,887,000 after acquiring an additional 160,155 shares during the period. Finally, Neumeier Poma Investment Counsel LLC purchased a new stake in shares of Prestige Consumer Healthcare in the first quarter valued at $8,713,000. Hedge funds and other institutional investors own 99.95% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Canaccord Genuity Group reduced their target price on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Finally, Royal Bank Of Canada raised shares of Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $93.33.

Prestige Consumer Healthcare Stock Up 0.7%

Prestige Consumer Healthcare stock traded up $0.4350 during midday trading on Thursday, hitting $65.4850. 546,401 shares of the company's stock were exchanged, compared to its average volume of 392,521. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. Prestige Consumer Healthcare Inc. has a 12 month low of $62.95 and a 12 month high of $90.04. The firm has a 50-day moving average of $76.03 and a two-hundred day moving average of $81.31. The company has a market cap of $3.22 billion, a PE ratio of 15.37, a P/E/G ratio of 2.07 and a beta of 0.43.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.01 by ($0.06). Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business had revenue of $249.53 million for the quarter, compared to the consensus estimate of $260.71 million. During the same quarter in the previous year, the company earned $0.90 earnings per share. The firm's revenue was down 6.6% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. As a group, analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.